GORT

Reviews

Boston Scientific Receives Fda Approval For Promus Premier

Di: Everly

December 2, 2013 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the Promus Premier Everolimus-Eluting Platinum Chromium

Promus PREMIER - Clinical Outcomes - Boston Scientific

SUMMARY OF SAFETY AND EFFECTIVENESS DATA

The PROMUS Stent is a private-labeled XIENCE™ V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed

At Boston Scientific, unwavering commitment to patients translates into the highest levels of research, quality, and innovation. Read the latest press releases.

July 26, 2014 — Take away the everolimus-eluting polymer from Boston Scientific’s FDA-approved Promus PREMIER™ stent and what do you have? The REBEL bare metal stent, which just

APPROVAL FOR THE FOLLOWING CHANGES TO THE PROMUS® ELEMENT PLUS EVEROLIMUS-ELUTING PLATINUM-CHROMIUM CORONARY STENT SYSTEM:

December 2, 2013 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the Promus Premier Everolimus-Eluting Platinum Chromium

At Boston Scientific, unwavering commitment to patients translates into the highest levels of research, quality, and innovation. Read the latest press releases. Read the latest press

The Promus PREMIER Stent System offers physicians improved DES performance in treating patients with coronary artery disease, and features unique customized

Approval marks transition to internally manufactured everolimus eluting stent in the U.S.NATICK, Mass., Boston Scientific Corporation announces U.S. Food and Drug

Advanced Stent Technology to Launch Immediately in the United States NATICK, Mass., Nov. 25, 2013 — Boston Scientific Corporation has received U.S. Food and Drug

NATICK, Mass., Feb. 12, 2013 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the

Boston Scientific has launched its Promus Premier everolimus-eluting platinum chromium coronary stent system in Japan, and is the company’s next-generation durable

At Boston Scientific, unwavering commitment to patients translates into the highest levels of research, quality, and innovation. Read the latest press releases. Read the

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA)

Boston Scientific Receives FDA Approval for REBEL™ Platinum Chromium Coronary Stent System Advanced Bare-Metal Stent Provides Additional Treatment Option for

NATICK, Mass., Nov. 25, 2013 /PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and

Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients. Marlborough, MA /PRNewswire/ – Boston Scientific Corporation

At Boston Scientific, unwavering commitment to patients translates into the highest levels of research, quality, and innovation. Read the latest press releases.

Boston Scientific launches Promus Premier stent in Europe - MassDevice

The Promus PREMIER Stent System was developed with extensive input from interventional cardiologists and is designed to provide best in class acute and clinical outcomes. It features

The Promus PREMIER Stent System was developed with extensive input from interventional cardiologists and is designed to provide best in class acute and clinical

NATICK, Mass., Nov. 25, 2013 /PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and

Approval for reduction in the stent primer drying time for the PROMUS stent.

Approval for the promus element plus and promus premier everolimus-eluting platinum chromiumcoronary stent systems (monorail and over-the-wire).

Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary

characteristics of the Promus PREMIER Stent System are described in Table 2.1. Table 2.1 Promus PREMIER™ Stent System Product Description Promus PREMIER Monorail™ Stent